A Phase III Study to Evaluate the Efficacy and Safety of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Are Naive to Complement Inhibitor Therapy

PHASE3RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 20, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

PNH

Interventions

DRUG

HSK39297 tablets

200mg QD for 24 weeks

DRUG

Eculizumab Injection

Eculizumab Injection for 24 weeks

Trial Locations (2)

RECRUITING

The First Affiliated Hospital of Nanjing Medical University, Nanjing

RECRUITING

The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou

All Listed Sponsors

lead

Haisco Pharmaceutical Group Co., Ltd.

INDUSTRY